Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 3 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President, head of Commercial Strategy and Corporate Affairs | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 694.37 | 15,000 shares | ||||
| d) | Aggregated information
| 15,000 shares DKK 694.37 | |||
| e) | Date of the transaction | 2023-11-02 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Instagram, X, LinkedIn andYouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Elizabeth DeLuca (US) +1 609 580 9868 edel@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company Announcement No 69 / 2023
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Mandatory notification of trade and acceptance by primary insiders11.12.2023 17:12:12 CET | Press release
Reference is made to the stock exchange announcement on 7 December 2023 whereby BW Sirocco Holdings AS (the "Offeror") announced the completion and settlement of the Offer and the acquisition of the Offeror of 30,000,561 shares, representing approximately 95.21% of the total number of shares in BW Ideol AS. The Offeror, being a close associate of Marco Beenen, the chairperson of the board of directors of BW Ideol AS, attach the required notifications of trade to this announcement. Further, mandatory notifications from other primary insiders and their related parties are also attached to this announcement. For further information, please contact: BW Ideol AS Nicolas de Kerangal (Chief Financial & Partnerships Officer) +33 (0) 7 76 87 70 08 / ir@bw-ideol.com (mailto:ir@bw-ideol.com) BW Sirocco Holdings AS Anders S. Platou (Chief Strategy Officer BW Offshore Limited) +47 99 71 86 55 Attachment Project Sirocco - PDMR - Attachments
LambdaTest and Wipro Collaborate for Innovative Gen AI Solutions11.12.2023 17:00:00 CET | Press release
LambdaTest and Wipro forge a pioneering partnership, integrating Wipro’s Gen AI-powered QE capabilities with LambdaTest’s HyperExecute, to revolutionize software testing on the Cloud with advanced AI capabilities. San Francisco , Dec. 11, 2023 (GLOBE NEWSWIRE) -- LambdaTest, a leading cloud-based unified testing platform is partnering with Wipro Limited, a leading technology services and consulting company, to revolutionize software testing by integrating Wipro’s Gen AI powered QE platform IntelliAssure with HyperExecute - a continuous cloud test orchestration solution offered by Lambdatest. The partnership aims to provide organizations that are modernizing and migrating to the cloud with an easy-to-implement, plug-and-play solution for infusing analytics-driven intelligence across their testing lifecycle for improved productivity as well as hyper-accelerated release cycle times. LambdaTest and Wipro's collaborative integration promises cutting-edge capabilities with an aim to enrich t
Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub11.12.2023 16:30:00 CET | Press release
Press Release Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub Nokia Bell Labs is reaffirming its commitment to New Jersey, upholding its 80-year heritage of cutting-edge research and innovation in the state.Move will establish New Brunswick as Nokia’s new R&D hub on the East Coast and affirms Nokia’s commitment to this fast-growing innovation zone in the US. 11 December 2023 New Brunswick, New Jersey – Nokia today announced plans to relocate its campus in Murray Hill, NJ by 2028 to a new state-of-the-art research and development (R&D) facility in the burgeoning innovation and technology hub in New Brunswick, NJ. The new leading-edge R&D facility will propel Nokia Bell Labs to adapt and evolve to remain at the forefront of cutting-edge technology and continue contributing to a legacy of innovation in New Jersey. As the industrial research arm of Nokia, Nokia Bell Labs has always moved ahead of
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties11.12.2023 16:30:00 CET | Press release
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties Pursuant to article 19 of the EU Regulation 596/2014 and according to a power of attorney given by Anne Mette Toftegaard, Alm. Brand A/S is required to file information on trading in shares in Alm. Brand A/S or other securities related to these shares by executives and their related parties. Please see attached report. Contact Please direct any questions regarding this announcement to: Senior Investor Relations Officer Mikael Bo Larsen, Mobile no. +45 51 43 80 02 Attachment AS 26 2023 - Report on trading Anne Mette Toftegaard
Nokia launches new venture partnerships and venture studio to maximize commercial potential of Nokia Bell Labs’ innovations11.12.2023 16:30:00 CET | Press release
Press Release Nokia launches new venture partnerships and venture studio to maximize commercial potential of Nokia Bell Labs’ innovations Nokia Innovation Framework evolving with new venture studio and venture partnerships to unleash the full commercial potential of Nokia Bell Labs technologies outside of Nokia’s strategic perimeters. A new venture studio with America’s Frontier Fund and Roadrunner Venture Studios for commercializing the next generation of critical technology for the US will be situated in New Jersey, the iconic home of Bell Labs innovation for over 80 years.New venture partnership with Celesta Capital will invest in scaling ventures built with deep technologies from Nokia Bell Labs. 11 December 2023 Murray Hill, New Jersey – Nokia today announced an evolution to its Innovation Framework to unlock the full commercial potential of Nokia Bell Labs’ innovations across industries and expand efforts in external startup creation in the US with new partnerships and a new vent